Free Trial

Xencor (NASDAQ:XNCR) Trading Down 4.3% - Time to Sell?

Xencor logo with Medical background

Xencor, Inc. (NASDAQ:XNCR - Get Free Report)'s share price fell 4.3% during mid-day trading on Friday . The company traded as low as $8.99 and last traded at $8.88. 20,578 shares traded hands during trading, a decline of 97% from the average session volume of 783,331 shares. The stock had previously closed at $9.28.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on XNCR. Wedbush reissued an "outperform" rating and set a $31.00 target price on shares of Xencor in a research note on Wednesday, April 30th. Wall Street Zen lowered shares of Xencor from a "hold" rating to a "sell" rating in a report on Friday, March 14th. Barclays reduced their target price on Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a research note on Thursday, May 8th. Finally, William Blair assumed coverage on Xencor in a research note on Monday, April 21st. They set an "outperform" rating on the stock. Two investment analysts have rated the stock with a sell rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $28.00.

View Our Latest Report on XNCR

Xencor Stock Down 4.8%

The company has a market cap of $628.43 million, a price-to-earnings ratio of -2.89 and a beta of 0.85. The company has a debt-to-equity ratio of 0.16, a quick ratio of 5.89 and a current ratio of 5.89. The stock's fifty day moving average is $8.50 and its two-hundred day moving average is $12.89.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.06). Xencor had a negative return on equity of 31.94% and a negative net margin of 181.17%. The company had revenue of $32.73 million during the quarter, compared to analysts' expectations of $23.44 million. During the same period last year, the company earned ($1.11) earnings per share. The business's revenue for the quarter was up 104.6% compared to the same quarter last year. Sell-side analysts predict that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Richard J. Ranieri sold 2,993 shares of the business's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $9.22, for a total transaction of $27,595.46. Following the transaction, the director directly owned 19,183 shares in the company, valued at approximately $176,867.26. The trade was a 13.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kurt A. Gustafson sold 2,993 shares of Xencor stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $9.22, for a total transaction of $27,595.46. Following the transaction, the director directly owned 20,183 shares in the company, valued at approximately $186,087.26. This represents a 12.91% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 15,810 shares of company stock valued at $154,123. 4.76% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Xencor

A number of hedge funds and other institutional investors have recently modified their holdings of XNCR. Primecap Management Co. CA lifted its holdings in Xencor by 8.6% during the first quarter. Primecap Management Co. CA now owns 9,761,012 shares of the biopharmaceutical company's stock worth $103,857,000 after acquiring an additional 776,580 shares during the period. Vanguard Group Inc. raised its stake in shares of Xencor by 5.5% during the 4th quarter. Vanguard Group Inc. now owns 8,017,366 shares of the biopharmaceutical company's stock worth $184,239,000 after purchasing an additional 418,040 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Xencor by 2.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,036,412 shares of the biopharmaceutical company's stock worth $92,758,000 after buying an additional 107,350 shares during the last quarter. BVF Inc. IL grew its position in Xencor by 19.7% during the first quarter. BVF Inc. IL now owns 2,740,141 shares of the biopharmaceutical company's stock valued at $29,155,000 after buying an additional 451,381 shares during the period. Finally, TCG Crossover Management LLC increased its holdings in Xencor by 1.0% during the fourth quarter. TCG Crossover Management LLC now owns 2,452,138 shares of the biopharmaceutical company's stock worth $56,350,000 after buying an additional 25,000 shares during the last quarter.

Xencor Company Profile

(Get Free Report)

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Featured Articles

Should You Invest $1,000 in Xencor Right Now?

Before you consider Xencor, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xencor wasn't on the list.

While Xencor currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Hot Growth Stocks to Watch Right Now!
Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines